Yesterday I helped a reader learn more about a new, experimental anti-myeloma drug, MDX-1097. Here is another question I received yesterday.
JP from India wrote:
My wife 67 is patient of relapsed and refractory Myeloma. Doctors feel that she has exhausted the available regimen including Thal + Dex+ Zometa; Alkeram + Dex; Bortezomib+ Dex ; Lenaliodomide + Dex; Bortezomib+ Dex till Dec’09 when she was asymptomatic. After a sudden and severe relapse in Feb last she has received intesive salvage therapy: Vin.,Mel. Cyclo.,Pred., PLD + Bort + Dex; and more recently Bendamustine. Our only hope is to enrol for clinical trials of Carfilzomib or pomalidomide But we live at New Delhi,India. I am not aware of any such trials being conducted in India although we have very good doctors and hospitals. Can any body help me in enrolling her with the on going international trial of Carfilzomib?
Unfortunately, this may be a tougher question to answer right away. I tried to research JP’s question on several world-wide research study locators. No luck. I did learn that, like a number of other recent drug studies, one of carfilzomib’s early Stage 1 studies was run in India. I will check with officials at Onyx Pharmaceuticals, makers of carfilzomib, to try and help PJ Monday–so stay tuned.
Feel good and keep smiling! Pat